Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes

NCT01123980 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01123980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01123980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2010
Completion date
June 30, 2011
Enrollment
521 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2